Next |
home / stock / incy / incy message board
Subject | By | Source | When |
---|---|---|---|
$INCY bears are running | chmcnfunds | investorshub | 05/01/2023 6:42:04 AM |
Price now | chmcnfunds | investorshub | 04/27/2023 4:15:20 PM |
short squeeze article | ValueInvestor15 | investorshub | 04/27/2023 9:03:03 AM |
$INCY What do you make of this? | $Pistol Pete$ | investorshub | 04/25/2023 12:51:51 PM |
Found an interesting article | TREND1 | investorshub | 04/22/2023 10:50:51 PM |
Thoughts on where this is headed? | Inoviorulez | investorshub | 04/22/2023 10:32:02 PM |
MomentumIts gaining up | north40000 | investorshub | 04/20/2023 6:18:15 AM |
$INCY The gaining last up | stocktrademan | investorshub | 04/18/2023 11:16:57 PM |
Price now | whytestocks | investorshub | 04/14/2023 3:59:02 AM |
Do we have a winner?Turn around time? | magness | investorshub | 04/12/2023 5:43:09 AM |
$INCY Do we have a winner?Turn around time? | Invest83838 | investorshub | 04/04/2023 7:11:32 PM |
$INCY Price trading last trade up | TREND1 | investorshub | 04/04/2023 8:29:22 AM |
$INCY short data if anyone is interested | chmcnfunds | investorshub | 04/02/2023 8:23:38 PM |
$INCY The trading | DewDiligence | investorshub | 04/02/2023 5:21:00 PM |
$INCY The trading last trade up | north40000 | investorshub | 04/02/2023 9:04:20 AM |
$INCY MomentumIts gaining last up | Fibanotch | investorshub | 04/02/2023 5:06:09 AM |
whytestocks: $INCY News Article - Caris Life Sciences and Incyte Enter Into Broad Precision Medicine | whytestocks | investorshangout | 03/07/2023 1:15:49 PM |
whytestocks: $INCY News Article - Incyte and CMS Announce Collaboration and License Agreement for Ru | whytestocks | investorshangout | 12/02/2022 4:55:48 PM |
Ouch Ouch Ouch! | Frankestin | investorshub | 03/01/2022 8:54:44 AM |
whytestocks: $INCY News Article - Data From Incyte's Oncology Portfolio Accepted for Presentation at | whytestocks | investorshangout | 05/12/2021 8:25:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million. Escient’s pipe...
EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic inducible urticaria and is in a Phase 2 study for chronic spontaneous urticaria E...
2024-04-12 12:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...